In 2015, Sanders et al.developed the only existing synthetic ABHD5 ligands, which may beuseful to target lipid disorders such as obesity, diabetes, and cardiovasculardiseases, because of their ability to promote fat catabolism.70 The authors considered previous studies assessingthat PLIN1 suppresses lipolysis by binding ABHD5, thus preventingABHD5-mediated activation of ATGL. This evidence concerns the gene ABHD5 and obesity due to melanocortin 4 receptor deficiency.